Peringatan Keamanan

There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.T78

Medrogestone

DB09124

small molecule approved withdrawn

Deskripsi

Medrogestone (INN), also known as 6,17?-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option.A31526 It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.L1118 It was never approved by the FDA.

Struktur Molekul 2D

Berat 340.507
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of medrogestone is reported to be of 4 hours.[T79]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

When administered, medrogestone presents a very rapid gastrointestinal absorption with a bioavailability of 100%. The maximum serum concentration of medrogestone is 10-15 ng/ml.T79

Metabolisme

The non-protein bound fraction of medrogestoneis available for metabolism.T80 The main route in the metabolism of medrogestone is hydroxylation.T79

Rute Eliminasi

The elimination time of medrogestone is of 36 hours.T79

Interaksi Obat

217 Data
Ulipristal The therapeutic efficacy of Medrogestone can be decreased when used in combination with Ulipristal.
Lepirudin Medrogestone may decrease the anticoagulant activities of Lepirudin.
Bivalirudin Medrogestone may decrease the anticoagulant activities of Bivalirudin.
Alteplase Medrogestone may decrease the anticoagulant activities of Alteplase.
Urokinase Medrogestone may decrease the anticoagulant activities of Urokinase.
Reteplase Medrogestone may decrease the anticoagulant activities of Reteplase.
Anistreplase Medrogestone may decrease the anticoagulant activities of Anistreplase.
Tenecteplase Medrogestone may decrease the anticoagulant activities of Tenecteplase.
Abciximab Medrogestone may decrease the anticoagulant activities of Abciximab.
Drotrecogin alfa Medrogestone may decrease the anticoagulant activities of Drotrecogin alfa.
Streptokinase Medrogestone may decrease the anticoagulant activities of Streptokinase.
Dicoumarol Medrogestone may decrease the anticoagulant activities of Dicoumarol.
Ardeparin Medrogestone may decrease the anticoagulant activities of Ardeparin.
Phenindione Medrogestone may decrease the anticoagulant activities of Phenindione.
Fondaparinux Medrogestone may decrease the anticoagulant activities of Fondaparinux.
Pentosan polysulfate Medrogestone may decrease the anticoagulant activities of Pentosan polysulfate.
Dipyridamole Medrogestone may decrease the anticoagulant activities of Dipyridamole.
Heparin Medrogestone may decrease the anticoagulant activities of Heparin.
Enoxaparin Medrogestone may decrease the anticoagulant activities of Enoxaparin.
Epoprostenol Medrogestone may decrease the anticoagulant activities of Epoprostenol.
Coumarin Medrogestone may decrease the anticoagulant activities of Coumarin.
Ximelagatran Medrogestone may decrease the anticoagulant activities of Ximelagatran.
Desmoteplase Medrogestone may decrease the anticoagulant activities of Desmoteplase.
Defibrotide Medrogestone may decrease the anticoagulant activities of Defibrotide.
Ancrod Medrogestone may decrease the anticoagulant activities of Ancrod.
Beraprost Medrogestone may decrease the anticoagulant activities of Beraprost.
Prasugrel Medrogestone may decrease the anticoagulant activities of Prasugrel.
Sulodexide Medrogestone may decrease the anticoagulant activities of Sulodexide.
Semuloparin Medrogestone may decrease the anticoagulant activities of Semuloparin.
Idraparinux Medrogestone may decrease the anticoagulant activities of Idraparinux.
Cangrelor Medrogestone may decrease the anticoagulant activities of Cangrelor.
Astaxanthin Medrogestone may decrease the anticoagulant activities of Astaxanthin.
Apixaban Medrogestone may decrease the anticoagulant activities of Apixaban.
Otamixaban Medrogestone may decrease the anticoagulant activities of Otamixaban.
Amediplase Medrogestone may decrease the anticoagulant activities of Amediplase.
Dabigatran etexilate Medrogestone may decrease the anticoagulant activities of Dabigatran etexilate.
Danaparoid Medrogestone may decrease the anticoagulant activities of Danaparoid.
Dalteparin Medrogestone may decrease the anticoagulant activities of Dalteparin.
Tinzaparin Medrogestone may decrease the anticoagulant activities of Tinzaparin.
(R)-warfarin Medrogestone may decrease the anticoagulant activities of (R)-warfarin.
Nadroparin Medrogestone may decrease the anticoagulant activities of Nadroparin.
Triflusal Medrogestone may decrease the anticoagulant activities of Triflusal.
Ditazole Medrogestone may decrease the anticoagulant activities of Ditazole.
Vorapaxar Medrogestone may decrease the anticoagulant activities of Vorapaxar.
Edoxaban Medrogestone may decrease the anticoagulant activities of Edoxaban.
Sodium citrate Medrogestone may decrease the anticoagulant activities of Sodium citrate.
Dextran Medrogestone may decrease the anticoagulant activities of Dextran.
Bemiparin Medrogestone may decrease the anticoagulant activities of Bemiparin.
Parnaparin Medrogestone may decrease the anticoagulant activities of Parnaparin.
Desirudin Medrogestone may decrease the anticoagulant activities of Desirudin.
Antithrombin Alfa Medrogestone may decrease the anticoagulant activities of Antithrombin Alfa.
Protein C Medrogestone may decrease the anticoagulant activities of Protein C.
Antithrombin III human Medrogestone may decrease the anticoagulant activities of Antithrombin III human.
Letaxaban Medrogestone may decrease the anticoagulant activities of Letaxaban.
Darexaban Medrogestone may decrease the anticoagulant activities of Darexaban.
Betrixaban Medrogestone may decrease the anticoagulant activities of Betrixaban.
Nafamostat Medrogestone may decrease the anticoagulant activities of Nafamostat.
Monteplase Medrogestone may decrease the anticoagulant activities of Monteplase.
Gabexate Medrogestone may decrease the anticoagulant activities of Gabexate.
Protein S human Medrogestone may decrease the anticoagulant activities of Protein S human.
Brinase Medrogestone may decrease the anticoagulant activities of Brinase.
Tioclomarol Medrogestone may decrease the anticoagulant activities of Tioclomarol.
Melagatran Medrogestone may decrease the anticoagulant activities of Melagatran.
Saruplase Medrogestone may decrease the anticoagulant activities of Saruplase.
(S)-Warfarin Medrogestone may decrease the anticoagulant activities of (S)-Warfarin.
Tocopherylquinone Medrogestone may decrease the anticoagulant activities of Tocopherylquinone.
Dabigatran Medrogestone may decrease the anticoagulant activities of Dabigatran.
Argatroban Medrogestone may decrease the anticoagulant activities of Argatroban.
Warfarin Medrogestone may decrease the anticoagulant activities of Warfarin.
Phenprocoumon Medrogestone may decrease the anticoagulant activities of Phenprocoumon.
Acenocoumarol Medrogestone may decrease the anticoagulant activities of Acenocoumarol.
4-hydroxycoumarin Medrogestone may decrease the anticoagulant activities of 4-hydroxycoumarin.
Rivaroxaban Medrogestone may decrease the anticoagulant activities of Rivaroxaban.
Ethyl biscoumacetate Medrogestone may decrease the anticoagulant activities of Ethyl biscoumacetate.
Ticagrelor Medrogestone may decrease the anticoagulant activities of Ticagrelor.
Fluindione Medrogestone may decrease the anticoagulant activities of Fluindione.
Clorindione Medrogestone may decrease the anticoagulant activities of Clorindione.
Diphenadione Medrogestone may decrease the anticoagulant activities of Diphenadione.
Troxerutin Medrogestone may decrease the anticoagulant activities of Troxerutin.
Edetic acid Medrogestone may decrease the anticoagulant activities of Edetic acid.
Reviparin Medrogestone may decrease the anticoagulant activities of Reviparin.
Dermatan sulfate Medrogestone may decrease the anticoagulant activities of Dermatan sulfate.
SR-123781A Medrogestone may decrease the anticoagulant activities of SR-123781A.
Human C1-esterase inhibitor The risk or severity of thromboembolism can be increased when Medrogestone is combined with Human C1-esterase inhibitor.
Conestat alfa The risk or severity of thromboembolism can be increased when Medrogestone is combined with Conestat alfa.
Butalbital The serum concentration of Medrogestone can be decreased when it is combined with Butalbital.
Pentobarbital The serum concentration of Medrogestone can be decreased when it is combined with Pentobarbital.
Secobarbital The serum concentration of Medrogestone can be decreased when it is combined with Secobarbital.
Methohexital The serum concentration of Medrogestone can be decreased when it is combined with Methohexital.
Thiopental The serum concentration of Medrogestone can be decreased when it is combined with Thiopental.
Primidone The serum concentration of Medrogestone can be decreased when it is combined with Primidone.
Methylphenobarbital The serum concentration of Medrogestone can be decreased when it is combined with Methylphenobarbital.
Thiamylal The serum concentration of Medrogestone can be decreased when it is combined with Thiamylal.
Phenobarbital The serum concentration of Medrogestone can be decreased when it is combined with Phenobarbital.
Amobarbital The serum concentration of Medrogestone can be decreased when it is combined with Amobarbital.
Hexobarbital The serum concentration of Medrogestone can be decreased when it is combined with Hexobarbital.
Barbital The serum concentration of Medrogestone can be decreased when it is combined with Barbital.
Barbexaclone The serum concentration of Medrogestone can be decreased when it is combined with Barbexaclone.
Butabarbital The serum concentration of Medrogestone can be decreased when it is combined with Butabarbital.
Phenytoin The serum concentration of Medrogestone can be decreased when it is combined with Phenytoin.

Target Protein

Progesterone receptor PGR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 4288903
    Revesz C, Chappel CI: Biological activity of medrogestone: a new orally active progestin. J Reprod Fertil. 1966 Dec;12(3):473-87.
Textbook
  • Jones & Bartlett (2016). 2016 Nurse's drug handbook (15th ed., pp. 985). Jones and Bartlett Publishers Inc..
  • Clark M., Harvey R., Finkel R., Rey J. and Whalen K. (2011). Pharmacology (5th ed.). Lippincott Williams & Wilkins.
  • Hinman F. (1983). Benign prostatic hypertrophy (1st ed.). Kingsport Press.
  • Lobo R., Crosignani P., Paoletti R. and Bruschi F. (2002). Women's health and menopause (1st ed.). Kluwer Academic Publishers.
  • Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Colprone Tab 5mg
    Tablet • 5 mg / tab • Oral • Canada • Approved
  • Colprone Tab 5mg
    Tablet • 5 mg / tab • Oral • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul